Gastroesophageal Adenocarcinoma Completed Phase 1 / 2 Trials for Alisertib (DB05220)

IndicationStatusPhase
DBCOND0030813 (Gastroesophageal Adenocarcinoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01045421Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesTreatment